Bank of America Initiates Coverage on Pharmasset (VRUS) with a Buy.
More News related to VRUS
- After-Hours Movers 2/9: MCZ, NTGR, CYBI, BIDU, RMTR, FNSR Higher; QUIK, LGF, APPY, VRUS, EXBD Lower
- Pharmasset, Inc. (VRUS) Posts Q4 Loss of $0.49, Wider than Expectations
- Pharmasset Reports Fiscal First Quarter 2010 Financial Results
- Pharmasset (VRUS) Files $150M Mixed Shelf
- Pharmasset Announces Exercise of Underwriter's Option
More News related to New Coverage
- Janney Montgomery Scott Initiates Coverage on Papa John's International (PZZA) with a Neutral
- Feltl & Co. Initiates Coverage on ActivIdentity (ACTI) with a Buy
- Oscar Gruss Initiates Coverage Airgas (ARG) with a Buy
- Sidoti & Co Initiates Coverage on Solutia (SOA) with a Buy
- RBC Capital Initiates Coverage on Questar (STR) with a Sector Perform
Bank of America initiates coverage on Pharmasset (Nasdaq: VRUS) with a Buy. Price target $27.
To see more analyst ratings on VRUS Click Here.
Pharmasset, Inc., a clinical-stage pharmaceutical company, focuses on discovering, developing, and commercializing drugs to treat viral infections.
Related Categories
New CoverageStocks Mentioned
+0.40Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
